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Abstract
In order to characterize the antiviral activity of human TRIM5α in more detail human derived
indicator cell lines over expressing wild type human TRIM5α were generated and challenged with
HIV-1 and HIV-2 viruses pseudotyped with HIV envelope proteins in comparison to VSV-G
pseudotyped particles. HIV envelope protein pseudotyped particles (HIV-1[NL4.3], HIV-1[BaL])
showed a similar restriction to infection (12 fold inhibition) compared to VSV-G pseudotyped
viruses after challenging TZM-huTRIM5α cells. For HIV-2 a stronger restriction to infection was
observed when the homologous envelope protein Env42S was pseudotyped onto these particles
compared to VSV-G pseudotyped HIV-2 particles (8.6 fold inhibition versus 3.4 fold inhibition). It
has been shown that HIV-2 is restricted by the restriction factor Lv2, acting on capsid like TRIM5α.
A mutation of amino acid 73 (I73V) of HIV-2 capsid renders this virus Lv2-insensitive. Lv2-
insensitive VSV-G pseudotyped HIV-2/I73V particles showed a similar restriction to infection as did
HIV-2[VSV-G] particles (4 fold inhibition). HIV-2 envelope protein (Env42S)-pseudotyped HIV-2/
I73V particles revealed a 9.3 fold increase in infection in TZM cells but remained restricted in TZM-
huTRIM5α cells (80.6 fold inhibition) clearly indicating that at least two restriction factors, TRIM5α
and Lv2, act on incoming HIV-2 particles. Further challenge experiments using primary isolates
from different HIV-1 subtypes and from HIV-1 group O showed that wild type human TRIM5α
restricted infection independent of coreceptor use of the infecting particle but to variable degrees
(between 1.2 and 19.6 fold restriction).
Findings
TRIM5 proteins of different species inhibit infectivity of a
range of different retroviruses in a species-specific fashion
[1,2]. Whereas rhesus macaque TRIM5α (rhTRIM5α) effi-
ciently restricts human immunodeficiency virus type 1
(HIV-1) replication (up to 100 fold reduction in viral
titer), the human homologue shows limited but repro-
ducible activity against HIV-1 (2 to 3 fold reduction in
viral titer), but restricts N-tropic strains of the murine
leukemia virus (N-MLV) very efficiently [3-8]. Different
human cell lines (e.g. HeLa, 293T, C134 cells) over
expressing a HA-tagged human TRIM5α have been used to
determine the efficiency of HIV-1 specific restriction.
Ylinen and colleagues showed that HIV-2 particles are
weakly restricted by human TRIM5α expressed in TE671
cells and efficiently restricted by rhesus TRIM5α [9], thus
showing a similar phenotype as HIV-1 particles.
In addition to TRIM5α it was shown that a yet unidenti-
fied restriction factor expressed in human cells restricts
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acts on incoming HIV-2 particles like TRIM5α but can be
bypassed if VSV-G pseudotyped HIV-2 particles are used
to challenge target cells [10-12].
The viral capsid of HIV-1 is the main target for the antivi-
ral effect, since certain mutations in the capsid protein
(for example exchange of glycine to valine or alanine at
position 89, G89V and G89A respectively) have been
shown to confer resistance to TRIM5α mediated restric-
tion [5,13-15]. For HIV-2 it has been shown that particles
encoding the amino acid valine at position 73 are insensi-
tive to Lv2-mediated restriction [11].
Most published studies to detect post entry restrictions
have used viral particles pseudotyped with vesicular sto-
matitis virus glycoprotein (VSV-G). This allows the deter-
mination of species-specific restrictions independent
from the expression of the appropriate receptors for infec-
tion [16-19] and indicates an independence from the
route of viral entry (plasma membrane fusion vs endocy-
totic uptake) for the observed restriction of HIV-1,
whereas Lv-2 mediated restriction of HIV-2 is entry route
dependent [10-12].
In order to use authentic viral particles (primary isolates
from different subtypes, including HIV-1 group O) for the
characterization of human TRIM5α mediated restriction,
the indicator cell line TZM-bl [20] was stably transduced
with a retroviral vector (LNCX2, Clonetech, Germany)
encoding wild-type, non-tagged human TRIM5α
(obtained from PD Bieniasz, [21]) and G418 resistant
cells were selected. TZM-bl cells are HeLa-cell derivatives
that express high levels of CD4 and both co-receptors
CXCR4 and CCR5, and are stably transduced carrying a
LTR-driven firefly luciferase as well as a LTR-driven β-
galactosidase cassette. Challenging these indicator cells
with HIV-1 and HIV-2 isolates results in the induction of
luciferase and β-galactosidase allowing easy detection of
infection and titration. In the absence of an antibody to
measure endogenous or low level TRIM5α expression, a
quantitative light-cycler RT-PCR protocol specific for the
SPRY-domain was established. Total RNA (2 μg) were
used to generate cDNA (superscript II, Invitrogen) using
an oligo-dT primer. An aliquot of this cDNA was used as
target for the SPRY-specific PCR (primers SP(+): 5'-CCTT-
TCATTGTGCCCCT-3'; SP(-): 5'-GCACAGAG TCAT-
GGGAC-3') as well as for the β-actin-specific PCR
(primers: actin(+): 5'-GGGTCAGAAGGATTCCTATG-3';
actin(-): 5'-GGTCTCAAACATGATCTGGG-3') in order to
normalize the cDNA input. The detection limit for both
PCR amplifications in the presence of SYBR-green was
determined using serial dilutions of plasmids containing
the target sequences and revealed a threshold of 103 mol-
ecules per reaction. Using this established qPCR protocol
a 2 fold over expression of TRIM5α mRNA in the newly
selected TZM-huTRIM5α cells (10384 ± 1032 mRNA mol-
ecules versus 5102 ± 531 mRNA molecules in TZM-
LNCX2 cells, normalized for β-actin cDNA) was deter-
mined. Next, the new indicator cells were challenged with
VSV-G pseudotyped B-MLV particles, known to be insen-
sitive to TRIM5α-mediated restriction. Both cell lines were
equally well infected using B-MLV particles (550 ng RT per
infection as determined using an RT-ELISA, Innovagen,
Sweden) transducing a GFP-reporter cassette (51.2% GFP-
positive TZM-LNCX2 cells and 50.0% GFP-positive TZM-
huTRIM5α, respectively) showing that both cell lines sup-
port efficient retroviral infection. The selected cells
expressed similar levels of CD4, CXCR4 and CCR5 on the
cell surface and maintained a functional tat-inducible fire-
fly luciferase and β-galactosidase reporter cassette like the
parental TZM-bl cell line (data not shown), thus are suit-
able indicator cells to study the influence of human
TRIM5α over expression on HIV envelope mediated infec-
tion.
First, infection experiments were performed using VSV-G
pseudotyped, HIV-1NL4.3 envelope and HIV-1BaL envelope
pseudotyped HIV-1 particles encoding for wild-type cap-
sid using increasing infectious units. TZM-bl cells trans-
duced with the empty vector LNCX2 and G418 selected
were used as reference (TZM-LNCX2). The induction of β-
galactosidase due to infection of TZM-bl cells (5 × 103
cells per well) was determined using a luminometer at day
2 post challenge through cell lysis and addition of specific
substrates (beta-glo Assay, Promega, Germany). The max-
imal detectable β-galactosidase activity after challenge of
TZM-LNCX2 cells was set to 100% for the different pseu-
dotyped particles (HIV-1[VSV-G], HIV-1[NL4.3], HIV-
1[BaL]). As figure 1A shows, the over expression of wild-
type human TRIM5α in TZM cells results in substantial
restriction to infection for all three viruses to a similar
extend. HIV-1[VSV-G] infection was 15.3 fold restricted,
whereas the HIV-1 envelope pseudotyped particles
showed a 12.6 fold and 12.7 fold restriction for HIV-
1[NL4.3] and HIV-1[BaL] respectively. This strong restric-
tion was unexpected, since only a 2 fold over expression
of TRIM5α mRNA was detected and previous studies
reported only a 2–3 fold restriction of HIV-1 by human
TRIM5α [3-8]. However, these studies used cells over
expressing HA-tagged TRIM5α, which in the case of rhesus
TRIM5α has been described to be less efficient in restrict-
ing SIVmac infection [7]. Whether the HA-tagged TRIM5α
is less stable or less active than wild type TRIM5α or other
factors differ between TZM-bl cells and HeLa cells influ-
encing retroviral restriction efficiency needs to be further
elucidated. However, the results obtained clearly indicate
that human TRIM5α is capable to restrict HIV-1 infection
quite substantially but that the restriction due to TRIM5α
is entry route independent (VSV-G versus HIV-1 enve-Page 2 of 7
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R5 tropic).
Next, the restriction of HIV-2 infection due to human
TRIM5α expression in TZM cells was analyzed. Like for
the pseudotyped HIV-1 particles, HIV-2 reporter viruses
encoding for renilla luciferase (similar to the HIV-1
reporter viruses used before) were generated through
transfection of 293T cells with the proviral ROD/A-Δen-
vRen plasmid and the expression plasmid for either VSV-
G or Env42S envelope protein (MP11-VSV-G and MP11-
Env42S, respectively) [22]. MP11-Env42S encodes for the
envelope protein of the TCLA isolate HIV-2CBL23. In addi-
tion, a Lv2-insensitive HIV-2 variant was constructed. The
proviral ROD/A-ΔenvRen plasmid (encoding isoleucine
at position 73 of the capsid protein, shown to cause a Lv2-
sensitive phenotype in the context of the molecular clone
HIV-2MCR) was mutagenized to exchange isoleucine at
position 73 to valine resulting in a Lv2-insensitive
HIV2ROD variant (HIV-2/I73V) similar to HIV-2MCN [11].
The resulting proviral plasmid (ROD/A/I73V-ΔenvRen)
was used to generate VSV-G and Env42S envelope pseudo-
typed particles. Using increasing infectious doses to chal-
lenge TZM-huTRIM5α cells a 3.4 and 4.8 fold restriction
of VSV-G pseudotyped HIV-2 and HIV-2/I73V particles
could be determined (fig. 1B). This result is in agreement
with earlier studies using CRFK cells expressing human
TRIM5α after challenge with VSV-G pseudotyped HIV-
2ROD [9] but shows in addition that the Lv2-insensitive
HIV-2/I73V remains restricted by human TRIM5α.
The challenge experiments with HIV-2 envelope protein
Env42S pseudotyped HIV-2 particles (HIV-2[Env42S] and
HIV-2/I73V[Env42S]) however confirmed again our pre-
vious observation that the Lv2-mediated restriction is
entry route dependent [10,11,22]. As figure 1C shows, the
over expression of human TRIM5α in TZM cells results in
a 2.5 times stronger restriction to infection for Env42S-
pseudotyped HIV-2 particles (8.6 fold restriction) com-
pared to VSV-G pseudotyped HIV-2 particles (3.4 fold
restriction). For HIV-2/I73V[Env42S] a 9.3 fold increase
in infection of TZM-LNCX2 cells compared to HIV-
2[Env42] was observed, indicating the escape from Lv2-
mediated restriction due the single amino acid change in
the capsid protein. Compared to the control cells TZM-
LNCX2 the over expression of human TRIM5α resulted in
a 80.6 fold restriction to infection. However, since the
restriction of HIV-2/I73V[Env42S] on TZM-huTRIM5α
cells was not changed compared to HIV-2[Env42S] one
can conclude again that the Lv2-insensitive HIV-2/I73V
remains restricted by human TRIM5α. Furthermore, the
only 2 fold increase of human TRIM5α mRNA in TZM-
huTRIM5α cells is sufficient to confer a maximal restric-
tion, even for the Lv2-insensitive HIV-2/I73V variant.
In order to analyse the human TRIM5α mediated restric-
tion of primary isolates and molecular clones of different
HIV-1 subtypes (A to D, G, J, CRF_AG and HIV-1 group O)
(obtained through the NIH AIDS Research and Reference
Reagent Program or described in further detail in [23-25])
the new indicator cells TZM-huTRIM5α and the control
cells TZM-LNCX2 were challenged with 2 × 103 infectious
units, as titrated on parental TZM-bl cells (equals a MOI
of 0.2), and again the induction of β-galactosidase two
days post infection was determined. As figure 2 shows,
some HIV-1 isolates tested were only marginally restricted
(1.2 to 1.4 fold for UG021, BD6 and ZA003) whereas the
vast majority of isolates was restricted between 2.2 and 5.2
fold. Three exceptional strong restricted isolates could be
identified, namely D117 (subtype B), ELI (subtype D) and
MVP8167 (group O), being restricted between 16.6 and
19.5 fold compared to the control cells TZM-LNCX2.
These three primary isolates are CXCR4-tropic variants.
However, the mean restriction to infection for the remain-
ing 18 isolates tested was 3.0 ± 1.3 fold, indicating that
there are no significant coreceptor-specific differences
between the X4-tropic (mean 2.5 ± 1.5 fold restriction for
7 isolates) and R5-tropic (mean 3.2 ± 1.2 fold restriction
for 11 isolates) variants studied. In comparison to the
experiments performed with pseudotyped particles, a
weaker restriction to infection with HIV-1NL4.3 versus HIV-
1[NL4.3] was observed. NL4.3 envelope pseudotyped par-
ticles derived from 293T transfections resulted in a higher
ratio of infectious units per ng RT/ml as compared to HIV-
1NL4.3 virus stocks obtained from PBMC cultures. There-
fore, PBMC derived virus stocks might contain a larger
proportion of virus-like particles able to abrogate
TRIM5α, resulting in a weaker restriction to infection,
which could explain the observed difference in restriction
efficiency. However, the quantity of virus-like particles per
virus preparation for the other virus stocks used is not
known and difficult to address. As for the three outliers in
this study it is tempting to speculate that they might not
only be restricted by TRIM5α but also by Lv2 or yet
another unknown restriction factor, as we could show in
this study that both TRIM5α and Lv2 restriction factors
can act on incoming HIV-2 capsids. However, further
studies are needed together with the identification of the
restriction factor Lv2.
Taken together our results show that even a moderate over
expression of wild-type human TRIM5α in human cells (2
fold as determined by quantitative RT-PCR) confers sub-
stantial restriction to infection for HIV-1 (12.7 fold restric-
tion for pseudotyped HIV-1 particles) but only a weaker
restriction to infection for HIV-2 (between 3.4 and 4.8
fold restriction for pseudotyped HIV-2 particles). This
overall stronger restriction to infection described here
compared to previous reports [3-8] could be explained by
non-tagged human TRIM5α being more stable than thePage 3 of 7
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(A) VSV-G envelope and HIV-1 envelope protein pseudotyped viruses are equally restricted by human TRIM5αFigure 1
(A) VSV-G envelope and HIV-1 envelope protein pseudotyped viruses are equally restricted by human TRIM5α. Titration of 
HIV-1[VSV-G], HIV-1[NL4.3] and HIV-1[BaL] viruses onto TZM-LNCX2 cells (closed symbols) and TZM cells expressing 
human TRIM5α(open symbols) result in 15.3 fold, 12.6 fold and 12.7 fold restriction to infection. (B) VSV-G pseudotyped Lv2-
sensitive and Lv2-insensitive HIV-2 viruses are restricted by human TRIM5α. HIV-2[VSV-G] and HIV-2/I73V[VSV-G] viruses 
were used to infect TZM-LNCX2 cells (closed symbols) and TZM-huTRIM5α cells (open symbols). Human TRIM5α restricted 
VSV-G mediated HIV-2 infection 3.6 fold and 4.8 fold, respectively. (C) HIV-2 envelope pseudotyped HIV-2 particles reveal 
entry route dependent Lv2-mediated restriction. HIV-2[Env42S] and HIV-2/I73V[Env42] viruses were used to infect TZM-
LNCX2 cells (closed symbols) and TZM-huTRIM5αcells (open symbols). The capsid mutation at position 73 (I73V) confers 
escape from Lv2-mediated restriction on TZM-LNCX2 cells (9.3 fold increase in infection), whereas the over expression of 
human TRIM5α in TZM-huTRIM5α cells results in a maximal restriction for both virus variants. Representative results from 
three independent experiments done in triplicate are shown. All virus preparations were titrated on the parental cell line 

























































































Retrovirology 2006, 3:79 http://www.retrovirology.com/content/3/1/79HA-tagged variant most often used in those studies. There
is also the possibility that the HA-tag on TRIM5α causes a
reduction in the activity as a restriction factor, as has been
described for the rhesus TRIM5α variant [7]. In addition,
other unidentified factors that differ between Hela-cells
and TZM-bl cells could account for the observed stronger
restriction and need to be further characterized. The chal-
lenge experiments using Lv2-sensitive and Lv2-insensitive
HIV-2 variants revealed that both Lv2 and human
TRIM5α act together on the incoming HIV-2 capsid and
that the 2 fold over expression of TRIM5α in TZM-
TRIM5α cells is sufficient to confer a maximal restriction
to infection. Since Lv2 has not been identified yet, the
endogenous level of Lv2 can not be determined. However,
the endogenous level of Lv2 in TZM-LNCX2 cells is suffi-
cient confer a 8.6 fold restriction to infection, indicating
Human TRIM5α mediated restriction varies between 1.2 and 19.5 fold independent of subtype or coreceptor usageFigure 2
Human TRIM5α mediated restriction varies between 1.2 and 19.5 fold independent of subtype or coreceptor usage. Different 
primary isolates of HIV-1 subtype A, B, C, D, G, J, CFR_AG and HIV-1 group O (2 × 103 infectious units per well) were used to 
infect TZM-huTRIM5α cells and the relative restriction to infection compared to TZM-LNCX2 cells was calculated. CXCR4 
tropic (A) and CCR5-tropic (B) virus isolates and molecular cloned viruses were used. Three independent experiments were 
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Retrovirology 2006, 3:79 http://www.retrovirology.com/content/3/1/79that Lv2 is a potent restriction factor. It has been described
that certain HIV-1 variants are also restricted by Lv2 [12].
Whether the three HIV-1 isolates D117, ELI and MVP8167
identified as being more efficiently restricted in TZM-
huTRIM5α cells are in addition susceptible to Lv2-medi-
ated restriction or restricted by yet another unidentified
factor needs to be further elucidated. There is no obvious
sequence similarity between HIV-1 and HIV-2 capsid
around amino acid position 73, where Lv2 susceptibility
has been mapped to. However, differences in viral uptake
or differences in activation of target cells due to envelope
binding, leading to more or less active restriction factors,
could also explain the observed strong restriction effi-
ciency for these three primary HIV-1 isolates and merit
further investigations.
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